Peptide News Digest

AIDS 2026 Opens in Rio, JAMA Pediatrics: Teen GLP-1 Use Hits 96%, Bloomberg Peptide Startup Race

AIDS 2026 pre-conferences open in Rio. JAMA Pediatrics: teen GLP-1 use 88.2% → 96.1%; bariatric surgery halves. Bloomberg peptide feature. Alnylam Thursday.

4 stories · Covering clinical-trials, research, industry

Editor's Note

Sunday's peptide news pivots to Rio de Janeiro. The 26th International AIDS Conference (AIDS 2026) pre-conference sessions open at Riocentro today with PATH, WHO, and Unitaid programming focused on advancing HIV prevention science and access, ahead of the main conference opening tomorrow Monday July 27 and the release of the UNAIDS 'United to End AIDS' report plus the WHO Global Health Sector Strategies mid-term assessment (halfway to the 2030 targets). Twice-yearly lenacapavir has been deployed in 10 priority sub-Saharan African countries; generic lenacapavir at approximately $40 per person per year is expected from Dr Reddy's, Hetero Labs, and other manufacturers in 2027. On the US obesity-drug front, JAMA Pediatrics published a UT Southwestern study Monday July 20 analyzing 204,000 adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database, documenting that GLP-1 monotherapy share rose from 88.2% to 96.1% while metabolic and bariatric surgery utilization fell from 11.6% to 3.7% over the study window. Bloomberg Businessweek published a long-form feature this week titled 'Peptides Fuel a Multibillion-Dollar Startup Race' covering the legalization gold rush and post-PCAC investor landscape. Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30 with analyst focus on the ALN-6222 obesity siRNA Phase 1 program.

Clinical Trials

26th International AIDS Conference (AIDS 2026) Pre-Conference Sessions Open Sunday July 26, 2026 in Rio de Janeiro at Riocentro With PATH, WHO, Unitaid, and Partner Programming on 'Advancing HIV Prevention Science and Access'; Twice-Yearly Lenacapavir (Gilead's Yeztugo) Now Deployed in 10 Priority Sub-Saharan African Countries With Generic Versions From Dr. Reddy's Laboratories, Hetero Labs, and Four Other Manufacturers Expected in 2027 at Approximately $40 Per Person Per Year Following Gates Foundation and Unitaid Partnership Announcements; Main Conference Opens Monday July 27 With UNAIDS 'United to End AIDS' Report Release and WHO Global Health Sector Strategies Mid-Term Assessment

The 26th International AIDS Conference (AIDS 2026) pre-conference sessions open Sunday July 26, 2026 at Riocentro in Rio de Janeiro, Brazil with PATH, WHO, and Unitaid programming focused on 'Advancing HIV Prevention Science and Access' between 08:00-13:00 local time. Twice-yearly lenacapavir (Gilead's Yeztugo, FDA-approved June 2025) has been deployed in 10 priority sub-Saharan African countries including South Africa (Secunda, Mpumalanga launch by President Cyril Ramaphosa on June 5, 2026), Zambia, and Eswatini through PEPFAR and Global Fund investments. Generic versions from Dr. Reddy's Laboratories, Hetero Labs, and four other manufacturers are expected in 2027 at approximately $40 per person per year following Gates Foundation and Unitaid partnership announcements in September 2025 (compared to the current US Yeztugo list price of approximately $28,218 per person per year). The main conference opens Monday July 27 with the UNAIDS 'United to End AIDS' report release providing 2025 HIV data and the WHO's first global mid-term assessment of progress under the Global Health Sector Strategies on HIV, viral hepatitis, and sexually transmitted infections (marking the halfway point to the 2030 targets). Up to 10,000 attendees are expected in person and virtually across the seven-day program running through Friday July 31. Conference theme: 'Rethink. Rebuild. Rise.'

#aids-2026 #lenacapavir #yeztugo #gilead #hiv-prevention #sub-saharan-africa #pepfar #global-fund #gates-foundation #unitaid #unaids #generic-lenacapavir #rio-de-janeiro
Research

JAMA Pediatrics Publishes UT Southwestern Retrospective Cohort Study Monday July 20, 2026 Analyzing 204,000+ US Adolescents and Young Adults Ages 13-25 Treated for Obesity Between May 2022 and January 2026 in the Epic Cosmos Electronic Health Record Database: GLP-1 Receptor Agonist Monotherapy Share Rose From 88.2% (May-November 2022) to 96.1% (June 2025-January 2026), Metabolic and Bariatric Surgery (MBS) Share Fell From 11.6% to 3.7% Over the Same Window, and Combined GLP-1 + MBS Use Remained Rare at Approximately 0.2%; Severe Obesity Currently Affects Approximately 9% of Ages 12-18 in the US

JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study Monday July 20, 2026 examining GLP-1 receptor agonist and metabolic and bariatric surgery (MBS) utilization patterns among 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. Key findings: the share of patients using only GLP-1 drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026); the share of patients undergoing MBS fell from 11.6% to 3.7% over the same window; combined GLP-1 + MBS use remained rare at approximately 0.2%. The study documents a substitution effect from surgical obesity treatment toward pharmacologic obesity treatment in the youth population over 44 months of coverage. Context: severe obesity currently affects approximately 9% of US adolescents ages 12-18. The findings raise questions about long-term efficacy, weight-regain risk after GLP-1 discontinuation in adolescents, and the appropriate role of MBS in adolescents whose obesity is unresponsive to GLP-1 pharmacotherapy. The study covers the pediatric analog of the earlier adult utilization-shift patterns already documented in the Kaiser Permanente and Optum electronic health record data.

#jama-pediatrics #glp-1 #adolescent-obesity #young-adult-obesity #bariatric-surgery #metabolic-surgery #ut-southwestern #epic-cosmos #retrospective-cohort #utilization-shift
Industry

Bloomberg Businessweek Publishes Long-Form Feature 'Peptides Fuel a Multibillion-Dollar Startup Race' Framing the Post-PCAC-Vote Investor Landscape as a Legalization Gold Rush and Profiles the Compounding-Pharmacy, Telehealth, Manufacturing, and Startup Ecosystem Positioning to Capture the Estimated $10-19 Billion Non-GLP-1 Peptide Market Analyst Jonah Lupton Projected for Hims & Hers by 2030 if the Company Captures 4-5% of Combined GLP-1 and Non-GLP-1 Peptide Markets Following the July 23-24 PCAC 6-of-7 Recommendation

Bloomberg Businessweek published a long-form feature this week titled 'Peptides Fuel a Multibillion-Dollar Startup Race' covering the peptide industry's post-PCAC-vote investor landscape. The story frames the July 23-24 PCAC recommendation of 6 of 7 peptides for the Section 503A Bulks List as the trigger for a legalization gold rush and profiles the compounding-pharmacy, telehealth, manufacturing, and startup ecosystem positioning to capture what analysts describe as the multibillion-dollar non-GLP-1 peptide market. The feature draws on the analyst framing established earlier in 2026 (Jonah Lupton's projection that Hims & Hers could generate $10-19 billion in annual peptide-related revenue by 2030 if the company captures 4-5% of combined GLP-1 and non-GLP-1 peptide markets) and profiles the venture-capital financing wave, including the General Bio $7.4 million seed round for oral peptide platform work (Axios Pro exclusive July 20), the MindRank $52 million Series B for AI-driven peptide discovery (July 10 digest coverage), and the Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide (July 19-20 digest coverage). The Bloomberg piece anchors the investment thesis on the 6-of-7 PCAC recommendation while noting that FDA rulemaking to actually add BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the 503A list takes 6-18 months per substance from the date the agency decides to act.

#bloomberg #peptide-market #post-pcac #startup-race #legalization-gold-rush #hims-hers #compounding-pharmacy #telehealth #venture-capital #samsung-polypeptide #mindrank #general-bio
Clinical Trials

Alnylam Pharmaceuticals (NASDAQ: ALNY) Q2 2026 Earnings Preview for Thursday July 30, 2026 Before Market Open; Analyst Focus Areas Include the New ALN-6222 Investigational Subcutaneous siRNA Obesity Phase 1 Trial (NCT07624071, First-in-Human Single-Ascending-Dose Design Enrolling 88 Adults With BMI 30-40 kg/m² Through December 2027 at Mount Royal, Canada), the ALN-2232 Phase 1 Weight-Management Program (Phase 1 Readout Expected Second Half of 2026), the Alnylam-PeptiDream Peptide-siRNA Conjugate Extrahepatic Delivery Platform Milestone Announced December 2025, and the Broader Alnylam 2030 Strategy Launch Positioning Beyond the Amvuttra (Vutrisiran) Transthyretin Amyloidosis Franchise

Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open. Analyst focus areas include the new ALN-6222 investigational subcutaneous siRNA obesity Phase 1 trial (NCT07624071, first-in-human single-ascending-dose randomized double-blind placebo-controlled design enrolling approximately 88 adults with BMI 30 to less than 40 kg/m² and HbA1c below 6.5% at a single site in Mount Royal, Canada through December 2027; molecular target of ALN-6222 has not been publicly disclosed). Also under focus: the Phase 1 ALN-2232 program (Alnylam's second obesity-track siRNA, with a Phase 1 readout expected in the second half of 2026), the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025 (demonstrating peptide-ligand-mediated targeted siRNA delivery to specific extrahepatic tissues), and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra (vutrisiran) transthyretin amyloidosis franchise. Alnylam's obesity pipeline is programmed against inhibin subunit beta E (INHBE) in liver and activin receptor type 1C (ACVR1C) in adipose tissue, both nucleic-acid modality targets that are distinct from GLP-1 agonism.

#alnylam #alny #q2-2026-earnings #aln-6222 #aln-2232 #sirna #obesity #peptidream #peptide-sirna-conjugate #extrahepatic-delivery #amvuttra #inhbe #acvr1c